Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.67 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676152 | 1.00 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7507547 | 0.98 | CYP11B2 (0.65) | CYP11B2CHRNB2CHRNA4SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4006926 | 0.98 | CYP11B2 (0.65) | CYP11B2CHRNB2CHRNA4SLC18A3SIGMAR1 | |
| SCHEMBL19566656 | 0.89 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4KDM1ACHRNA7 | |
| SCHEMBL717702 | 0.89 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4KDM1ACHRNA7 | |
| Hydrochloric Acid SCHEMBL2091699 | 0.87 | CYP11B2 (0.61) | CYP11B2CHRNB2CHRNA4KDM1ACHRNA7 | |
| SCHEMBL990213 | 0.86 | — | — | |
| SCHEMBL29848157 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL16755914 | 0.85 | CYP11B2 (0.50) | CYP11B2CHRNB2CHRNA4SLC18A3SIGMAR1 | |
| SCHEMBL2080108 | 0.84 | KDM1A (0.54) | CYP11B2CHRNB2CHRNA4KDM1ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | claimed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | claimed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | claimed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0272208-B1 | AROMATICALLY SUBSTITUTED AZACYCLO-ALKYLALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0272208-A1 | Aromatically substituted azacyclo-alkylalkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | CYP11B2 3517/4885CHRNB2 3835/4885CHRNA4 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.